Twin Blood 600. A molecular pathway for blood cancers.

A blood- or bone-marrow-based route that brings DNA and RNA together into the Twin.

Discuss the Blood 600 pathway See the Twin workflow

Overview

What this pathway is

OnKommon Twin · Twin Blood

DNA and RNA together, from blood or bone marrow.

Twin Blood 600 is the Twin testing route for blood cancers. It analyses DNA and RNA together, from a blood or bone-marrow sample. Reading both in one route matters in blood cancers, where mutations and gene fusions both drive the disease.

Intended audience and use

Who it is for

People with a blood cancer whose treating haematologist or oncologist is considering molecular profiling.

Sample and testing pathway

Sample and what is generated

Sample: Blood or bone marrow.
Information generated: DNA and RNA findings — mutations, fusions and expression — with the biomarkers integrated into the Twin.

From result to Twin

How the information enters Twin

Findings become the molecular foundation of the baseline Twin (TwinBirth) and are read through the analytical layers relevant to the data — for example SourceGuard for origin, RNA Expression & Signatures for fusion and expression information, and AccessMatch and TrialGraph for evidence and trials.

Analytical layers most relevant to this route

01 · Baseline — Day 0
Integrate the data. Build the Twin.
02 · During months 0–6
Review new findings inside the workflow.
03 · End of month 6
Review the evidence. Set the next pathway.
04 · After six months
Twin tracks
Track 12 Track 47 Track 118

Strengths

Why this route

DNA and RNA in one route — mutations and fusions read together.
Blood or bone marrow — no solid-tissue biopsy needed.
Built for haematological cancers, where fusions often define the disease.

How every finding is interpreted, from detection to decision

Deliverables

What you receive

A structured Twin report in the five documented components: executive molecular summary, molecular findings, treatment options to evaluate, clinical-trial matches and a longitudinal view.
Review and sign-off by the treating oncologist, within the KPCIRC sign-off process.
Entry into the six-month Twin journey, with the option to continue into a Twin track afterwards.

The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.

KPCIRC sign-off process

Questions

Frequently asked questions

Is blood or bone marrow better?

The appropriate sample depends on the diagnosis and the clinical question, and is decided by the treating haematologist or oncologist together with the laboratory's acceptance criteria.

Why DNA and RNA together?

Some important alterations in blood cancers, such as certain gene fusions, may be easier to detect in RNA, while others are DNA changes. This route reads both.

Does this route include pharmacogenomics?

Yes. Pharmacogenomics is among the integrated analytical features designed into Twin's panels.